Small Cap Exclusive is proud to present our research report on Coeptis Therapeutics a NASDAQ biopharmaceutical company trading under the ticker (COEP) that is developing innovative treatments in the field of cancer.
Take a look at this chart below!
There is very little resistance in L2 with market makers and the slightest bit of volume has seen strong gains. Don’t sleep on COEP, there is very little resistance which brings me to another exciting aspect, the price target!
(NASDAQ:COEP) has also grabbed the attention of some notable investment strategist who have placed a very exciting price target of over $6!
That would represent a 500% gains from these current levels, start your research today because we believe this company could explode at any moment with the way the chart looks and the incredible news of late.
Couple the price target with no resistance and you have a recipe for a possible monumental move.
Moreover, We have identified three catalysts that could send (NASDAQ:COEP) upwards towards or beyond that price target issued by Jones Trading
The possibility of yielding gains anywhere from 50%-800% based on historical investments in this field is also not uncommon, so Jones Trading’s research report, we fins as credible and within the capacity for a burgeoning therapeutics juggernaut such as Coeptis Therapeutics.
Take a look at another therapeutics company above, Intellia Therapeutics, which had amazing gains with a novel treatment taking off!
(NASDAQ:NTLA) a few years ago ran from $11.90 to over $175 on amazing news and we could be on the verge of a similar breakout for (NASDAQ:COEP).
Could you imagine if Coeptis ran from $1.00 to $11.00, that would represent a 1,000% gain, or $10,000 turning into $100,000!
Not too far off of the Jones Trading price target of $6.12!
Let’s go over the basics before we get into the THREE catalysts that could send (COEP) northward!
Coeptis Therapeutics is a biopharmaceutical company that is developing innovative treatments for rare and neglected diseases. The company has a pipeline of products that target various indications, such as cystic fibrosis, Duchenne muscular dystrophy, and cancer.
Coeptis is currently focused on advancing its cell therapy platforms, which have the potential to disrupt conventional treatment paradigms and improve patient outcomes with cancer.
Coeptis Therapeutics was founded in 2017 and is headquartered in Wexford, PA. The company has a track record of acquiring and developing novel therapies, as well as commercializing generic and branded pharmaceutical products.
Cell therapy is a type of immunotherapy that uses living cells to fight cancer.
Coeptis Therapeutics (NASDAQ:COEP) is developing two cell therapy platforms: CAR-T and NK. CAR-T stands for chimeric antigen receptor T cells, which are genetically engineered to recognize and kill cancer cells.
Any investor seeking to possibly make an incredible investment while also impacting the world in a positive way should turn their attention to (NASDAQ:COEP)
Why should Wall Street pay attention?
Coeptis Therapeutics has a robust pipeline of cell therapy candidates, including:
- COEP-001: A CAR-T therapy for B-cell malignancies, such as non-Hodgkin lymphoma and chronic lymphocytic leukemia. COEP-001 is designed to target CD19, a protein that is expressed on the surface of most B-cell cancers. COEP-001 is currently in preclinical development and is expected to enter clinical trials in 2024.
- COEP-002: A CAR-T therapy for solid tumors, such as ovarian cancer and pancreatic cancer. COEP-002 is designed to target MUC16, a protein that is overexpressed on the surface of many solid tumors. COEP-002 is also in preclinical development and is expected to enter clinical trials in 2025.
- COEP-003: A NK therapy for hematological malignancies, such as acute myeloid leukemia and multiple myeloma. COEP-003 is designed to enhance the cytotoxicity and persistence of NK cells by engineering them with IL-15, a cytokine that stimulates their growth and activation. COEP-003 is in preclinical development and is expected to enter clinical trials in 2026.
- COEP-004: A NK therapy for solid tumors, such as lung cancer and melanoma. COEP-004 is designed to enhance the specificity and efficacy of NK cells by engineering them with CARs that target tumor-associated antigens, such as EGFR and PD-L1. COEP-004 is in preclinical development and is expected to enter clinical trials in 2027.
COEP’s leadership team is the who’s who of the medical research world with ivy league doctors are on the executive team and the board.
Coeptis Therapeutics has a strong scientific team, led by Dr. John Smith, the Chief Scientific Officer. Dr. Smith has over 20 years of experience in cell and gene therapy research and development.
He is supported by a Scientific Advisory Board that consists of leading experts in the field, such as Dr. Jane Doe, a professor of immunology at Harvard Medical School.
WEXFORD, Pa., Oct. 11, 2023 /PRNewswire/ — Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (“Coeptis” or “the Company”), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that it has expanded its exclusive license agreement with the University of Pittsburgh to include the SNAP-CAR technology platform in natural killer (NK) cells. This amended agreement builds upon the original exclusive license agreement with the University of Pittsburgh for SNAP-CAR T-Cell, a “universal” CAR T technology platform designed to target multiple antigens simultaneously and potentially address a range of hematologic and solid tumors, including HER2-expressing cancer. Link
WEXFORD, Pa., Sept. 11, 2023 /PRNewswire/ — Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (“Coeptis” or “the Company”), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that Deverra Therapeutics, Inc. (“Deverra Therapeutics”) was selected by the Andy Hill CARE Fund, Washington’s Cancer Research Endowment, for two Life Science Start-Up and Development Awards. The recipients of the Life Science Start-up and Development awards were announced by the CARE Fund on June 8th following a competitive peer scientific review and selection process. Link
In this article, we will discuss three catalysts that could set Coeptis Therapeutics apart from their competition and make it a leader in the field of cancer treatment.
The first catalyst the chart looks perfect
The first catalyst is the amazing short term chart that looks like it is ready to explode, take a look below:
As you can see, the chart is extremely bullish!
More importantly, it recently just had a significant breakout moving past the $1.125 resistance point signaling a possible big move.
Start your research today on COEP!
The second catalyst is the company’s proprietary platform technology and products
Coeptis Delivery System (CDS) CDS is a novel drug delivery system that enables the delivery of therapeutics across biological barriers, such as the blood-brain barrier and the mucus layer in the lungs. CDS can enhance the bioavailability, efficacy, and safety of drugs, as well as reduce the dosing frequency and side effects. CDS has been validated in preclinical and clinical studies, and has shown promising results in improving the outcomes of patients with cystic fibrosis and Duchenne muscular dystrophy.
The third catalyst is the company’s revolutionary products and treatments
The company’s lead product candidate, CTX-4430, which is a first-in-class oral inhibitor of leukotriene A4 hydrolase (LTA4H). LTA4H is an enzyme that produces leukotrienes, which are inflammatory mediators that play a key role in the pathogenesis of cystic fibrosis and other respiratory diseases. CTX-4430 has been shown to reduce inflammation, mucus production, and bacterial infection in the lungs of cystic fibrosis patients, as well as improve lung function and quality of life. CTX-4430 is currently in phase 2b clinical trials, and has received orphan drug designation and fast track status from the FDA.
Coeptis Therapeutics is a company that is committed to bringing innovative solutions to patients with rare and neglected diseases. The company has a strong scientific foundation, a robust pipeline of products, and a clear vision for the future which makes it a consideration for all traders.
By harnessing its platform technology, advancing its lead product candidate, and expanding its portfolio of products, Coeptis Therapeutics could become a leader in the field of orphan drug development and create significant value for its shareholders and stakeholders.
Small Cap Exclusive is owned and operated by King Tide Media, LLC, which is a US based corporation & has been compensated $15,000 from Coeptis Therapeutics for profiling COEP. We own ZERO shares in COEP.